Literature DB >> 10366051

Efficacy, tolerability, and rare side effects of tibolone treatment in postmenopausal women.

C Egarter1, M Sator, P Berghammer, J Huber.   

Abstract

OBJECTIVE: The purpose of this study was to assess the tolerability and side effects of tibolone (Livial, Organon), a synthetic steroid analogue for the treatment of postmenopausal symptoms, in a large population of patients.
METHOD: 1189 postmenopausal patients were included in this study. The patients' blood pressure, body weight, general complaints, and the severity of their climacteric complaints were documented at baseline and after 4 months of tibolone treatment.
RESULTS: Tibolone significantly relieved all of the classical menopausal complaints. The proportion of patients with bleeding problems dropped significantly from 15.9% to 6.8%. Other complaints, such as headache, vertigo, nervousness, breast tenderness, and hirsutism were also significantly less frequent than before treatment. Only few women reported other rare side effects, and only 14.4% of women discontinued treatment prematurely.
CONCLUSION: Tibolone provides an efficient and safe means of treating the postmenopausal syndrome in every-day practice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10366051     DOI: 10.1016/s0020-7292(99)00002-8

Source DB:  PubMed          Journal:  Int J Gynaecol Obstet        ISSN: 0020-7292            Impact factor:   3.561


  3 in total

Review 1.  Hot flashes: aetiology and management.

Authors:  D Barton; C Loprinzi; D Wahner-Roedler
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

2.  A Comparative Study of CEE, Tibolone, and DHEA as Hormone Replacement Therapy for Surgical Menopause.

Authors:  Bhawna Gupta; Preeti Mittal; Rakesh Khuteta; Adarsh Bhargava
Journal:  J Obstet Gynaecol India       Date:  2012-11-10

Review 3.  Updated clinical recommendations for the use of tibolone in Asian women.

Authors:  K-E Huang; R Baber
Journal:  Climacteric       Date:  2010-08       Impact factor: 3.005

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.